Physician

Samah Nassereddine, M.D

According to 2025 Medicare claims, Samah Nassereddine, M.D (NPI: 1235552290) practices hematology/oncology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from The District, DC. This provider's primary affiliated billing organization is MEDICAL FACULTY ASSOCIATES, INC (NPI: 1417990581; TIN: 522220700) and primary practice location at 20037-3201. Nassereddine is affiliated with the PBACO Holding, LLC (ACO ID: A1001), participating under the MSSP model.

Nassereddine's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 235 traditional Medicare patients, billed 24,878 HCPCS/CPT codes, and received $283,606 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 651 prescription claims across 104 beneficiaries totaling $1,104,589 in drug costs, led by Calquence (Acalabrutinib Maleate). Open Payments data shows 9 records totaling $207. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $225,985 to $283,606. In contrast, Part D prescription costs have risen steadily, from $1,813 to $1,104,589. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	80	8,774	$225,985
2021	357	72,877	$1,733,727
2022	224	33,033	$255,995
2023	228	20,263	$228,526
2024	235	24,878	$283,606

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	24	$1,813
2016	18	102	$6,311
2017	N/R	27	$2,555
2018	N/R	14	$42,749
2019	N/R	14	$75,154
2020	18	34	$31,289
2021	54	263	$472,020
2022	64	303	$774,725
2023	87	356	$519,000
2024	104	651	$1,104,589

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	80	253	$154
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	27	28	$147
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	106	177	$102
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	49	62	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	39	127	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	25	750	$387,965
Brukinsa	Zanubrutinib	13	390	$160,309
Eliquis	Apixaban	140	6,494	$124,705
Sprycel	Dasatinib	12	360	$122,208
Xarelto	Rivaroxaban	89	5,225	$95,183

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$207	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

Hematology/oncology providers in the Washington, DC-MD market
Providers within practice ZIP code 20037-3201
Providers whose plurality patient county is The District, DC
Providers in District of Columbia whose primary affiliated billing organization is MEDICAL FACULTY ASSOCIATES, INC
Providers in District of Columbia affiliated with PBACO Holding, LLC (MSSP)

FAQ

What Medicare data is available for Samah Nassereddine, M.D?

Tedicare shows public-source Medicare data for Samah Nassereddine, M.D (NPI 1235552290), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Samah Nassereddine, M.D have ACO affiliation data?

Samah Nassereddine, M.D is shown with ACO affiliation data for PBACO Holding, LLC (MSSP, ACO ID A1001).

What billing organization is linked to Samah Nassereddine, M.D?

Samah Nassereddine, M.D is linked to MEDICAL FACULTY ASSOCIATES, INC (billing NPI 1417990581) in the available physician profile data.

Does Samah Nassereddine, M.D have Open Payments data?

Samah Nassereddine, M.D has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.